Michael Davidson Sells 64,708 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) CEO Michael Davidson sold 64,708 shares of the firm’s stock in a transaction dated Tuesday, February 24th. The shares were sold at an average price of $36.15, for a total value of $2,339,194.20. Following the sale, the chief executive officer owned 459,859 shares of the company’s stock, valued at $16,623,902.85. This represents a 12.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

NewAmsterdam Pharma Stock Up 3.4%

Shares of NASDAQ:NAMS opened at $35.46 on Friday. The company has a market cap of $4.08 billion, a PE ratio of -20.50 and a beta of 0.06. The company’s 50-day moving average price is $34.06 and its 200 day moving average price is $32.95. NewAmsterdam Pharma Company N.V. has a fifty-two week low of $14.06 and a fifty-two week high of $42.00.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its earnings results on Wednesday, February 18th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.23). The business had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.92 million. NewAmsterdam Pharma had a negative return on equity of 26.67% and a negative net margin of 906.22%. As a group, equities analysts anticipate that NewAmsterdam Pharma Company N.V. will post -1.75 EPS for the current year.

Institutional Investors Weigh In On NewAmsterdam Pharma

Several institutional investors have recently made changes to their positions in NAMS. Wells Fargo & Company MN increased its stake in NewAmsterdam Pharma by 50.0% in the 4th quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock worth $32,000 after buying an additional 300 shares during the period. Geode Capital Management LLC boosted its holdings in shares of NewAmsterdam Pharma by 0.4% during the fourth quarter. Geode Capital Management LLC now owns 102,395 shares of the company’s stock worth $3,590,000 after purchasing an additional 437 shares during the last quarter. Arizona State Retirement System grew its holdings in NewAmsterdam Pharma by 3.8% in the 3rd quarter. Arizona State Retirement System now owns 13,251 shares of the company’s stock valued at $377,000 after buying an additional 483 shares during the period. China Universal Asset Management Co. Ltd. raised its holdings in shares of NewAmsterdam Pharma by 2.4% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 22,549 shares of the company’s stock valued at $408,000 after buying an additional 521 shares during the period. Finally, The Manufacturers Life Insurance Company boosted its position in NewAmsterdam Pharma by 5.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 10,868 shares of the company’s stock valued at $197,000 after buying an additional 544 shares during the last quarter. Institutional investors own 89.89% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on NAMS shares. Cantor Fitzgerald reissued an “overweight” rating on shares of NewAmsterdam Pharma in a research report on Thursday, February 19th. Royal Bank Of Canada increased their price objective on NewAmsterdam Pharma from $44.00 to $47.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 21st. Stifel Nicolaus boosted their price objective on shares of NewAmsterdam Pharma from $44.00 to $50.00 and gave the company a “buy” rating in a research report on Tuesday, December 16th. Leerink Partners reiterated an “outperform” rating and issued a $55.00 price target on shares of NewAmsterdam Pharma in a research note on Tuesday, January 6th. Finally, Guggenheim raised their target price on NewAmsterdam Pharma from $41.00 to $45.00 and gave the stock a “buy” rating in a research report on Thursday, February 19th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $46.55.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.